Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma

FASEB Journal

Volumn 21, Issue 12, 2007, Pages 3153-3161

  Coutinho, Enia Lúcia ^a   Andrade, Luciana Nogueira De Sousa ^c   Chammas, Roger ^c   Morganti, Ligia ^b   Schor, Nestor ^a   Bellini, Maria Helena ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^c CEPID/FAPESP   (Brazil)

Author keywords

Antiangiogenesis; Bioassay; Cancer; Gene therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE 3; ENDOSTATIN; RETROVIRUS VECTOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SCID MOUSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VIRUS GENE; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; GENETIC TRANSDUCTION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

MURINAE; MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENDOSTATINS; GENE TRANSFER TECHNIQUES; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 35348879078     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-8412com     Document Type: Article

References (56)

1. Chow, W. H., Devesa, S. S., Warren, J. L., and Fraumeni, J. F. (1999) Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631
2. Mulders, P., Bleumer, I., and Oosterswijk, E. (2003) Tumor antigens and markers in renal cell carcinoma. Urol. Clin. N. Am. 30, 455-465
3. Jacobson, J., Rasmuson, T., Grankvist, K., and Ljungberg, B. (2000) Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 163, 343-347
4. Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Sato, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., et al. (1999) Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer 35, 133-137
5. Dirix, L. Y., Vermeulen, P. B., Pawinski, A., Prove, A., Benoy, I., De Pooter, C., Martin, M., De Pooter, C., and Van Oosterom, A. T.(1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 76, 238-243
6. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143, 1255-1262
7. Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., and Terada, M. (1994) Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 54, 4233-4237
8. Figlin, R. A. (1999) Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-386
9. Yagoda, A., and Bander, N. H. (1989) Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol. Int. 44, 338-345
10. Negrier, S., Escudier, B., Lasset, C., Douillard, J., Savary, J., Chevreau, C. Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) Recombinant human interleukin-2, recombinanthuman interferon alfa-2a, or both in metastatic renal-cell carcinoma. N. Engl. J. Med. 338, 1272-1278
11. Young, R. C. (1998) Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? N. Engl. J. Med. 338, 1305-1306
12. Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., and Bajamonde, A.(1998) Interferon-1b compared with placebo in metastatic renal-cell carcinoma. N. Engl. J. Med. 338, 1265-1271
13. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696
14. Cao, Y. (2001) Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33, 357-369
15. Folkman, J. (1995) Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763
16. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J.(1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285
17. MacDonald, N. J., Shivers, W. Y., Narum, D. L., Plum, S. M., Wingard, J. N., Fuhrmann, S. R., Liang, H., Holland-Linn, J., Chen, D. H., and Sim, B. K. (2001) Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin, J. Biol. Chem. 276, 25190-25196
18. Karumanchi, S. A., Jha, V., Ramchandran, R., Karihaloo, A., Tsiokas, L., Chan, B., Dhanabal, M., Hanai, J. I., Venkataraman, G., Shriver, Z., et al. (2001) Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 7, 811-822
19. Dixelius, J., Larsson, H., Sasaki, T., Holmqvist, K., Lu, L., Engstrom, A., Timpl, R., Welsh, M., and Claesson-Welsh, L. (2000) Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95, 3403-3411
20. Sasaki, T., Larsson, H., Kreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U. Hohenester, E., and Timpl, R. (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 18, 6240-6248
21. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., and Olsen, B. R. (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18, 4414-4423
22. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and Sukhatme, V. P. (1999) Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274, 11721-11722
23. Sauter, B. V., Martinet, O., Zhang, W. J., Mandeli, J., and Woo, S. L. (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. U. S. A. 97, 4802-4807
24. Feldman, A. L., Alexander[b], H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., and Libutti, S. K. (2001) Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 93, 1014-1020
25. Yamanaka, R., Zullo, S. A., Ramsey, J., Onodera, M., Tanaka, R., Blaese, M., and Xanthopoulos, K. G. (2001) Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene. Ther. 8, 796-802
26. Bellini, M. H., and Bartollini, P. (2003) Increases in weight of growth hormone-deficient and immunodeeficient (lit/Scid) dwarf mice after grafting of hGH secreting, primary human keratinocytes. FASEB J. 17, 2322-2324
27. Parkkila, S., Rajaniemi, H., Parkkila, A., Kivelä, J., Waheed, A., Pastoreková, S., Pastorek, J., and Sly, W. S. (2000) Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. U. S. A. 97, 2220-2224
28. Markowitz, D., Goff, S., and Bank, A. (1988) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406
29. Wilfred, T. V., Asarni, N., Fujirnoto, S., Mazda, O., and Yoshirnoto Katsura. (1994) Efficient retrovirus-mediated gene transduction into murine hematopoietic stem cells and longlasting expression using a transwell coculture system. Blood 84, 780-788
30. Streit, M., Stephen, A. E., Hawighorst, T., Matsuda, K., Lange-Asschenfeldt, B., Brown, L. F., Vacanti, J. P., and Detmar, M. (2004) Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy 1. Cancer Res. 62, 2004-2012
31. Gordower, L., Decaestecker, C., Kacem, Y., Lemmers, A., Gusman, J., Burchert, M., Danguy, A., Gabius, H., Salmon, I., Kiss, R., and Camby, I. (1999) Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol. 25, 319-330
32. Scappaticci, F. A., Smith, R., Pathak, A, Schloss, D., Lum, B., Cao, Y., Johnson, F., Engleman, E. G., and Nolan, G. P. (2001) Combination angiostatin and endostatin gene transfer induces synergistic anti-angiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 3, 186-196
33. Tomoharu, F., Masa-aki, N., Takushi, N., Tomoichiro, O., Natsuo, Hiro-omi, K., and Susumu, K. (2002) Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo. Urology 59, 6,973-977
34. Sabo, E., Boltenko, A., Sova, Y. Stein, A., Kleinhaus, S., and Resnick, M. B. (2001) Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin. Cancer Res. 7, 533-537
35. Folkman, J. (2006) Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci. STKE 354, 35-36
36. Dhanabal, M., Ramchandran, R., Vol, K. R., Stillman, I. E., Lombardo, M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, V. P. (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59, 189-197
37. Folkman, J. (1998) Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. U. S. A. 95, 9064-9066
38. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. (2002) Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov. 1, 415-426
39. Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehan, W. M., Yang, J. C., Fogler, W. E., Turner, E. M., Alexander, H. R., Jr, and Libutti, S. K. (2000) Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res. 6, 4628-4634
40. Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L., and Folkman, J. (1999) The generation of endostatin is mediated by elastase. Cancer Res. 59, 6052-6056
41. Brammer, R. D., Bramhall, S. R., and Eggo, M. C. (2005) Endostatin expression in a pancreatic cell line is modulated by a TNFalpha-dependent elastase. Br. J. Cancer 93, 1024-1028
42. Feldman, A. L., Alexander, H. R., Jr., Yang, J. C., Linehan, W. M., Eyler, R. A., Miller, M. S., Steinberg, S. M., and Libutti, S. K. (2002) Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95, 1637-1643
43. Kleinman, H. K., and Liau, G. J. (2001) Gene therapy for antiangiogenesis. Natl. Cancer Inst. 93, 965-967
44. Kurdow, R., Boehle, A. S., Ruhnke, M., Mendoza, R., Boenicke, L., Sipos, B., Schniewind, B., Dohrmann, P., and Kalthoff, H. (2003) Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model. Langenbecks. Arch. Surg. 388, 401-405
45. Sauter, B. V., Martinet, O., Zhang, W. J., Mandeli, J., and Woo, S. L. (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. U. S. A. 97, 4802-4807
46. Pulkkanen, K. J., Laukkanen, J. M., Fuxe, J., Kettunen, M. I., Rehn, M., Kannasto, J. M., Parkkinen, J. J., Kauppinen, R. A., Pettersson, R. F., and Yla-Herttuala, S. (2002) The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther. 9, 908-916
47. Szary, J., and Szala, S. (2001) Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int. J. Cancer 91, 835-839
48. Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehan, W. M., Yang, J. C., Fogler, W. E., Turner, E. M., Alexander, H. R., Jr., Libutti, S. K. (2000) Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage iv clear cell renal cancer; Clinical Cancer Res. 152, 4628-4634
49. Nangia-Makker, P., Honjo, Y., Sarvis, R., Akahani, S., Hogan, V., Pienta, K. J., and Raz, A. (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 156, 899-909
50. Fukushi, J., Makagiansar, I. T., and Stallcup, W. B. (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cel. 15, 3580-3590
51. Dhanabal, M., Volk, R., Ramchandran, R. Simons, M., and Sukhatme, V. P. (1999) Cloning, expression, and in vitro activity of human endostatin. Biochem. Biophys. Res. Commun. 258, 260-264
52. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and Sukhatme, V. P. (1999) Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274, 11721-11726
53. Yokoyama, Y., Dhanabal, M., Griffioen, A. W. Sukhatme, V. P., and Ramakrishnan, S. (2000) Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 60, 2190-2196
54. Ding, I., Sun, J. Z., Fenton, B., Liu, W. M., Kimsely, P., Okunieff, P., and Min, W. (2001) Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 61, 526-531
55. Van Wijngaarden, J., de Rooij, K., Van Beek, E., Bernsen, H., Que, I., Van Hinsbergh, V. W., and Lowik, C. (2004) Identification of differentially expressed genes in a renal cell carcinoma tumor model after endostatin- treatment. Lab. Invest. 84, 1472-1483
56. Dirkx, A. E., oude Egbrink, M. G., Castermans, K., van der Schaft, D. W., Thijssen, V. L., Dings, R. P., Kwee, L., Mayo, K. H., Wagstaff, J., Bouma-ter et al. (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyteendothelium interactions and infiltration in tumors. FASEB J. 20, 621-630